RegenMed Systems at ARPA-H Summit

RegenMed Systems founder and CMO, Dr. Daniel Kraft presented the MarrowMiner at the ARPA-H BioHybrid Device Summit held in New Orleans May 16-17th, 2024. Biohybrid devices merge advances in synthetic biology, bioelectronics, stem cells and materials science to treat conditions from diabetes to obesity to cancer.

RegenMed Systems Awarded Bill & Melinda Gates Foundation Research Award

The Bill & Melinda Gates Foundation (BMGF) awarded RegenMed Systems a $1.1M research award to study the use of the MarrowMiner in conjunction with gene therapy. The study is being conducted in collaboration with the Univ of Washington and the Fred Hutchinson Cancer Center. October, 2022

MarrowMiner Trial Results Published in BBMT

The results from the MarrowMiner were published in Transplantation and Cellular Therapy / Biology of Blood & Marrow Transplant (BBMT).